Torsten O Nielsen
Overview
Explore the profile of Torsten O Nielsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
203
Citations
18397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen M, Nielsen T, Bartlett J, Laenkholm A, Shepherd L, Ejlertsen B
NPJ Breast Cancer
. 2025 Mar;
11(1):26.
PMID: 40064871
NCIC-CTG MA.5 and DBCG 89D are symmetrically designed randomized trials comparing adjuvant cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in high-risk breast cancer patients. In a joint analysis...
2.
Shenasa E, He Y, Wang Z, Tu D, Gao D, Kos Z, et al.
Mod Pathol
. 2025 Jan;
38(5):100718.
PMID: 39863112
Assessment of the tumor-immune microenvironment can be used as a prognostic tool for improved survival and as a predictive biomarker for treatment benefit, particularly from immune-modulating treatments including cytotoxic chemotherapy....
3.
Shenasa E, Thornton S, Gao D, Kommoss F, Kommoss F, Nielsen T
Lab Invest
. 2025 Jan;
105(3):104091.
PMID: 39800049
Immunotherapy has emerged as a new treatment modality in some soft tissue sarcomas, particularly for tumors associated with tertiary lymphoid structures (TLSs). These structures are functional lymphoid aggregates, and their...
4.
Gupta A, Tinker A, Jonker D, Jamal R, Hirte H, Winquist E, et al.
EClinicalMedicine
. 2024 Dec;
79:102991.
PMID: 39737219
Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought...
5.
Hofvander J, Qiu A, Lee K, Bilenky M, Carles A, Cao Q, et al.
bioRxiv
. 2024 May;
PMID: 38798672
Synovial sarcoma (SyS) is an aggressive soft-tissue malignancy characterized by a pathognomonic chromosomal translocation leading to the formation of the SS18::SSX fusion oncoprotein. SS18::SSX associates with mammalian BAF complexes suggesting...
6.
Leon-Ferre R, Jonas S, Salgado R, Loi S, de Jong V, Carter J, et al.
JAMA
. 2024 Apr;
331(13):1135-1144.
PMID: 38563834
Importance: The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with...
7.
Pozner A, Li L, Verma S, Wang S, Barrott J, Nelson M, et al.
Nat Commun
. 2024 Feb;
15(1):1165.
PMID: 38326311
The t(X,17) chromosomal translocation, generating the ASPSCR1::TFE3 fusion oncoprotein, is the singular genetic driver of alveolar soft part sarcoma (ASPS) and some Xp11-rearranged renal cell carcinomas (RCCs), frustrating efforts to...
8.
Kos Z, Nielsen T, Laenkholm A
Cold Spring Harb Perspect Med
. 2023 Dec;
14(6).
PMID: 38151327
For more than a century, microscopic histology has been the cornerstone for cancer diagnosis, and breast carcinoma is no exception. In recent years, clinical biomarkers, gene expression profiles, and other...
9.
Pozner A, Verma S, Li L, Wang S, Barrott J, Nelson M, et al.
bioRxiv
. 2023 Oct;
PMID: 37873234
The t(X,17) chromosomal translocation, generating the ASPSCR1-TFE3 fusion oncoprotein, is the singular genetic driver of alveolar soft part sarcoma (ASPS) and some Xp11-rearranged renal cell carcinomas (RCC), frustrating efforts to...
10.
Benabdallah N, Dalal V, Scott R, Marcous F, Sotiriou A, Kommoss F, et al.
Nat Struct Mol Biol
. 2023 Sep;
30(11):1640-1652.
PMID: 37735617
The SS18-SSX fusion drives oncogenic transformation in synovial sarcoma by bridging SS18, a member of the mSWI/SNF (BAF) complex, to Polycomb repressive complex 1 (PRC1) target genes. Here we show...